Systematic (IUPAC) name
Clinical data
Legal status
  • Schedule I
CAS number
ATC code ?
Chemical data
Formula C14H19NO 
Mol. mass 217.3081 g/mol

4'-Methyl-α-pyrrolidinopropiophenone (4-MePPP, MPPP or MαPPP) is a stimulant drug. It is structurally very similar to α-PPP, with only one added methyl group in the para position on the phenyl ring. 4-MePPP was sold in Germany as a designer drug in the late 1990s and early 2000s,[1][2][3] along with a number of other pyrrolidinophenone derivatives.[4][5] Although it has never achieved the same international popularity as its better-known relations α-PPP and MDPV, 4-MePPP is still sometimes found as an ingredient of grey-market "bath salt" blends[6] such as "NRG-3".[6]

See also


  1. ^ Springer, D; Peters, FT; Fritschi, G; Maurer, HH (2002). "Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry". Journal of Chromatography B 773 (1): 25–33.  
  2. ^ Springer, D; Paul, LD; Staack, RF; Kraemer, T; Maurer, HH (2003). "Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes". Drug metabolism and disposition: the biological fate of chemicals 31 (8): 979–82.  
  3. ^ Springer, D; Fritschi, G; Maurer, HH (2003). "Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry". Journal of Chromatography B 796 (2): 253–66.  
  4. ^ Maurer, HH; Kraemer, T; Springer, D; Staack, RF (2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic drug monitoring 26 (2): 127–31.  
  5. ^ Staack, RF; Maurer, HH (2005). "Metabolism of designer drugs of abuse". Current drug metabolism 6 (3): 259–74.  
  6. ^ a b Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J (December 2010). "Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones". Drug Testing and Analysis 3 (9): 569–75.